[February 24, 2014]

N-of-One Presents Data at AGBT 2014 Reporting Uncommon BRAF Mutations in Up to 50% of BRAF Positive Tumors

N-of-One, the leading provider of molecular interpretation and therapeutic strategies for precision medicine for oncology, presented data suggesting that up to 50% of BRAF gene mutations can be found in locations other than the most common location, codon V600. In addition, though BRAF is most common in melanoma, N-of-One reported on BRAF mutations in others cancers as well, including lung, colorectal and thyroid cancers. N-of-One presented the data in a poster presentation at the Advances in Genome Biology and Technology (AGBT) meeting, held February 12-15, 2014 in Marco Island, Florida.

The findings were derived from a dataset of over 4,000 sequenced tumors N-of-One has interpreted, including 164 tumors cotaining BRAF alterations.

"These findings suggest that additional research to characterize BRAF mutations, both on codon V600 and other locations we've highlighted, could benefit many patients, not only those with melanoma but also those with other cancers that include BRAF mutations," said Dr. Jennifer Levin Carter, Chief Medical Officer of N-of-One. "In addition to standard-of-care therapy targeting V600, there is evidence that some of these additional mutations may be amenable to targeted therapy, specifically therapeutic approaches that may include MEK inhibitors and CRAF inhibitors (sorafenib). Using next-generation sequencing to explore the entire coding region of BRAF, in a variety of tumor types, will expand treatment options for patients and lead to the identification of more potentially targetable mutations."

About N-of-One

N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options. N-of-One's team of experts has interpreted more than 6,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists and through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.

[ Back To TMCnet.com's Homepage ]